Roche and Hansoh Pharmaceutical Group announced a new up-to-$15B+ collaboration focused on next-generation antibody-drug conjugates across multiple cancer types. The companies plan two preclinical Hansoh ADC programs plus additional programs driven by Roche targets, building on a prior Roche license for Hansoh’s HS-20110.